Literature DB >> 17971592

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.

Dennis S Chi1, Pedro T Ramirez, Jerrold B Teitcher, Svetlana Mironov, Debra M Sarasohn, Revathy B Iyer, Eric L Eisenhauer, Nadeem R Abu-Rustum, Yukio Sonoda, Douglas A Levine, Carol L Brown, Carol Aghajanian, David M Gershenson, William J Hoskins, Hedvig Hricak, Richard R Barakat.   

Abstract

PURPOSE: To compare surgeons' operative assessments of residual disease (RD) to those identified on postoperative computed tomography (CT) scans in patients with advanced ovarian carcinoma reported to have undergone optimal primary cytoreduction. PATIENTS AND METHODS: All patients at one of two institutions, who were scheduled to have primary surgery for presumed advanced ovarian cancer, were asked to consent to a postoperative CT scan if cytoreduction to < or = 1 cm RD was reported. CT scan findings were graded using a qualitative analysis scale from 1 (normal) to 5 (definitely malignant).
RESULTS: From January 2001 to September 2006, 285 patients were enrolled. A total of 78 patients met eligibility criteria and had postoperative CT scans. In 41 cases (52%), postoperative scan findings correlated with the surgical report of no RD more than 1 cm, and in seven cases (9%), the CT findings were indeterminate. In 10 cases (13%), more than 1 cm RD was noted by the radiologist as probably malignant, and in 20 cases (26%), definitely malignant. In these 30 cases, the radiologically reported median largest residual mass was 1.9 cm (range, 1.1 to 5.1), with RD more than 1 cm reported most commonly in the right upper quadrant (15 patients [50%]) and central abdomen (nine patients [30%]).
CONCLUSION: There was only a 52% correlation between surgeons' assessments and postoperative CT scan evaluations of RD in patients reported to have undergone optimal cytoreduction. Further study is required to determine whether this lack of correlation is due to rapid interval tumor regrowth, RD underestimated by the surgeons, and/or overestimated by the radiologists; and to determine the clinical implications of these discrepancies.

Entities:  

Mesh:

Year:  2007        PMID: 17971592     DOI: 10.1200/JCO.2007.12.2317

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Surgical debulking of ovarian cancer: what difference does it make?

Authors:  John O Schorge; Christopher McCann; Marcela G Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2010

2.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

3.  Progress in surgical oncology: Gynecology perspective.

Authors:  Nadeem R Abu-Rustum
Journal:  J Surg Oncol       Date:  2022-10       Impact factor: 2.885

4.  Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Ramez N Eskander; James Kauderer; Krishnansu S Tewari; Robert S Mannel; Robert E Bristow; David M O'Malley; Stephen C Rubin; Gretchen E Glaser; Chad A Hamilton; Keiichi Fujiwara; Warner K Huh; Frederick Ueland; Jean-Marie Stephan; Robert A Burger
Journal:  Gynecol Oncol       Date:  2018-03-15       Impact factor: 5.482

Review 5.  The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-16

6.  Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development.

Authors:  Evis Sala; Andrew N Priest; Masako Kataoka; Martin J Graves; Mary A McLean; Ilse Joubert; John R Griffiths; Robin A F Crawford; Mercedes Jimenez-Linan; Helena M Earl; James D Brenton; David J Lomas
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

7.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

8.  Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"?

Authors:  Marcello Ceccaroni; Giovanni Roviglione; Francesco Bruni; Roberto Clarizia; Giacomo Ruffo; Matteo Salgarello; Michele Peiretti; Stefano Uccella
Journal:  Surg Endosc       Date:  2017-10-19       Impact factor: 4.584

9.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?

Authors:  Yuki Himoto; Paulina Cybulska; Fuki Shitano; Evis Sala; Junting Zheng; Marinela Capanu; Stephanie Nougaret; Ines Nikolovski; Hebert A Vargas; Wei Wang; Jennifer J Mueller; Dennis S Chi; Yulia Lakhman
Journal:  Gynecol Oncol       Date:  2019-09-12       Impact factor: 5.482

Review 10.  Ovarian cancer staging: What the surgeon needs to know.

Authors:  Lucas Roberto Lelis Botelho de Oliveira; Natally Horvat; Pamela Ines Causa Andrieu; Pedro Sergio Brito Panizza; Giovanni Guido Cerri; Publio Cesar Cavalcante Viana
Journal:  Br J Radiol       Date:  2021-07-21       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.